TickerFacts.

Company research / URGN

UroGen Pharma Ltd. (URGN)

Build a valuation ↗↓ Download CSV

CIK 0001668243 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, UroGen Pharma Ltd. reported revenue of $109.79M. Revenue grew 21.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $188.73M.

Key ratios (year ended 2025-12-31)

88.7%
Gross margin
-113.7%
Operating margin
-139.8%
Net margin
21.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-09

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$188.73M$109.79M$90.40M$82.71M$64.36M$48.04M$11.80M$18.0K$1.13M$8.16M$17.53M
Cost of Revenue$17.28M$12.45M$8.88M$9.36M$7.65M$5.16M$1.01Mn/a$1.80M$600.0K$28.0K
Gross Profit$171.46M$97.34M$81.52M$73.35M$56.70M$42.88M$10.79M$18.0K-$675.0K$7.56M$17.50M
R&D Expense$61.26M$67.11M$57.15M$45.61M$52.91M$47.64M$47.31M$49.30M$36.93M$18.70Mn/a
Operating Income-$66.65M-$124.86M-$96.78M-$65.54M-$79.04M-$92.29M-$126.74M-$109.48M-$77.18M-$19.95M$798.0K
Depreciation & Amortization$308.0K$307.0K$329.0K$802.0K$924.0K$831.0K$416.0K$300.0K$400.0K$200.0K$200.0K
EBITDA-$66.34M-$124.56M-$96.45M-$64.73M-$78.12M-$91.46M-$126.32M-$109.18M-$76.78M-$19.75M$998.0K
Net Income-$97.64M-$153.49M-$126.87M-$102.24M-$109.78M-$110.82M-$128.48M-$105.15M-$75.66M-$20.00M-$1.94M
Total Assets$252.59M$200.46M$285.71M$178.31M$135.62M$119.75M$122.00M$202.39M$103.56M$75.55M$23.06M
Total Liabilities$384.99M$305.93M$294.51M$243.52M$224.98M$111.33M$25.65M$22.09M$13.46M$7.04M$6.75M
Long-Term Debt$200.00M$125.00Mn/an/an/an/an/an/an/an/an/a
Shareholders' Equity-$132.40M-$105.47M-$8.80M-$65.21M-$89.36M$8.41M$96.36M$180.30M$90.09M$68.52M$16.31M
Cash & Equivalents$79.13M$110.75M$171.99M$95.00M$55.41M$44.36M$52.86M$49.69M$101.32M$37.00M$21.36M
Operating Cash Flow-$158.92M-$162.44M-$96.77M-$76.38M-$87.56M-$84.89M-$105.89M-$71.02M-$37.33M-$9.57M$4.19M
Capital Expenditures$218.0K$289.0K$295.0K$194.0K$254.0K$752.0K$1.22M$325.0K$560.0K$271.0K$695.0K
Free Cash Flow-$159.13M-$162.73M-$97.06M-$76.57M-$87.81M-$85.64M-$107.10M-$71.34M-$37.89M-$9.84M$3.49M
Shares Outstanding48.87M48.35M42.23M32.49M23.13M22.46M22.17M21.03M16.21M13.75M2.31M
EPS (Basic)n/a-$3.19-$2.96-$3.55-$4.81-$4.96n/an/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView